Creative Planning
AMLX icon

Creative Planning’s Amylyx Pharmaceuticals AMLX Stock Holding History

Creative Planning’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Sell
15,881
-2,002
-11% -$31K ﹤0.01% 3610
2026
Q1 		$249K Buy
+17,883
New +$252K ﹤0.01% 3574

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Creative Planning's AMLX Position: Q2 2026 in Review

Creative Planning reduced its Amylyx Pharmaceuticals (AMLX) stake by 11% in Q2 2026, selling an estimated $31K and leaving 15,881 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #3610.

Creative Planning first reported a position in AMLX in Q1 2026 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Creative Planning held 15,881 shares of Amylyx Pharmaceuticals worth $285K as of Q2 2026.
  • Creative Planning sold 2,002 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $31K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3610 holding.
  • Creative Planning first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.